China Biotech Services Holdings Limited announced that on 21 January 2021, Shanghai Longyao received the approval letter for clinical trial from the National Medical Products Administration for Shanghai Longyao's product named LY007 Cellular Injection (LY007 Cellular Injection). The classification of the registration is Class I new drug. LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. LY007 Cellular Injection is currently the first and only CD20-targeted CAR-T product in China whose application for registered clinical trial has been approved. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence the Phase I clinical trial and study of LY007 Cellular Injection according to the submitted proposal. The National Medical Products Administration's approval of The company's clinical trial application for LY007 Cellular Injection demonstrates the company's capabilities in the research and development of immunocellular drugs.